CUSIP: 008064107
Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
28,456,703
-
Share change
-
+282,421
-
Total reported value
-
$841,465,274
-
Price per share
-
$29.57
-
Number of holders
-
80
-
Value change
-
+$12,906,968
-
Number of buys
-
40
-
Number of sells
-
27
Quarterly Holders Quick Answers
What is CUSIP 008064107?
CUSIP 008064107 identifies AVTE - Jade Biosciences, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2024
-
Previous quarter:
Q4 2023
Recent filing periods for CUSIP 008064107:
Institutional Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q1 2024
As of 31 Mar 2024,
Jade Biosciences, Inc. - COM (AVTE) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,456,703 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sofinnova Investments, Inc., TCG Crossover Management, LLC, Atlas Venture Life Science Advisors, LLC, BAKER BROS. ADVISORS LP, Frazier Life Sciences Management, L.P., Cormorant Asset Management, LP, GREAT POINT PARTNERS LLC, Driehaus Capital Management LLC, and BlackRock Inc..
This page lists
80
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.